Objective: To empirically derive the optimal measure of pharmacologic cardiovascular support in infants undergoing cardiac surgery with bypass and to assess the association between this score and clinical outcomes in a multi-institutional cohort. Design: Prospective, multi-institutional cohort study.
W ernovsky et al (1) proposed the use of an inotrope score to measure pharmacologic cardiovascular support given to infants after cardiac surgery. This score was neither derived from empiric data nor rigorously tested as a measure of illness severity. However, the Wernovsky score and its modifications have often been used as a measure of illness severity following cardiac surgery in children even though the score was not created for this purpose (2) (3) (4) (5) . The association between inotrope score and clinical outcomes after pediatric cardiac surgery has remained poorly defined in the literature, and clinical practice changes over the past decade suggested the need for a revision to the original inotrope score. Defining clinically relevant predictors of patient risk for morbidity and mortality, like an inotrope score, could help to inform intensivists who might then modify treatment in meaningful ways early in a patient's course.
To address this knowledge gap, we previously developed a vasoactive-inotropic score (VIS) and tested its association with clinical outcomes in a single-center cohort of children younger than 6 months undergoing cardiac surgery with cardiopulmonary bypass (CPB) (6) . In contrast to the original inotrope score (IS) proposed by Wernovsky et al (1) , this new score incorporates additional medications typically used in contemporary clinical practice. We demonstrated that the maximum VIS in the first 24 hours had a strong and consistent relationship with postoperative morbidity and mortality. Other authors subsequently performed similar analyses in single-center series of infants after cardiac surgery (7, 8) . These studies led to mixed conclusions about the optimal measure of VIS and the strength of association between VIS and clinical outcomes, particularly in neonates.
To further explore remaining questions about VIS, its association with clinical outcomes, and its usefulness as marker of illness severity in postoperative cardiac surgical patients, we performed a multicenter analysis of data reported to the Pediatric Cardiac Critical Care Consortium (PC 4 ), a new quality improvement collaborative of North American pediatric cardiac ICUs (CICU) and surgical programs. This study represents the first scientific contribution from the PC 4 collaborative. Our objective was to assess the association between measures of pharmacologic cardiovascular support and clinical outcomes in this multi-institutional cohort of patients from birth to 1 year of age at the time of surgery with CPB and specifically in a subgroup of neonates. We hypothesized that maximum VIS in the first 24 hours would perform as well or better than the IS in predicting important clinical outcomes and that we could define a cut point that would effectively discriminate patients likely to have morbidity and mortality in the postoperative period. registry. Additional data necessary for the analysis were prospectively collected for eligible patients (described below) and managed using Research Electronic Data Capture electronic data capture tools hosted by the PC 4 Data Coordinating Center (DCC) in Ann Arbor, MI (9) . These two datasets were merged at the DCC prior to analysis.
MATERIALS AND METHODS

Setting and Study
Study Design
This was a prospective cohort study inclusive of consecutive infants up to 1 year old at the time of surgery with CPB receiving postoperative care in the CICU at the four participating institutions. Patients were enrolled from November 1, 2011, to April 30, 2012. Patients were excluded from the analysis if one of the following criteria were met: 1) the patient returned from the operating room to the CICU on mechanical circulatory support, 2) the patient was transferred to a nonstudy institution before critical care services were discontinued, or 3) the patient had a previous surgical episode already captured in the study population (i.e., a patient could appear only once in the cohort). Each participating center received institutional review board (IRB) approval to collect data specific to this research study; the need for written informed consent was waived by each institution's IRB.
Data Collection and Data Integrity
Basic demographic and clinical data were collected routinely as part of the PC 4 /VPS databases. Interrater reliability (IRR) testing was performed by VPS/PC 4 , and each participating institution achieved an IRR more than 90% on the study variables prior to study initiation and quarterly thereafter. Other surgical data not captured in the PC 4 /VPS databases (e.g., anatomic diagnoses, procedure performed, and bypass times) were extracted from the local Society of Thoracic Surgeons Congenital Heart Surgery Database at each institution. As noted above, additional data necessary for the analysis were prospectively collected at each site in a supplementary data module on all eligible patients. This information included preoperative and hourly postoperative vasoactive medication use and the exact time at which clinical endpoints were reached. Operations were categorized using the Society of Thoracic SurgeonsEuropean Association for Cardiothoracic Surgery (STAT) risk stratification system (category 1 = lowest mortality risk; category 5 = highest mortality risk) (10) . Data from all sources were linked at the DCC using indirect identifiers (e.g., surgical date and age at surgery). Clinical outcomes were verified with the primary site investigator at each location and crosschecked between data sources. All out-of-range values were also reviewed with each data collection team prior to analysis. All investigators had access to the data presented here and reviewed and approved the current version of the article.
Measures of Cardiovascular Pharmacologic Support
Our analytic methods mirror those of our original publication (6) . Doses of vasoactive medications were recorded hourly for the first 48 hours after postoperative admission to the CICU. The full list of medications can be viewed in Appendix 1. We calculated the IS and the VIS as described previously (6) We also assessed the sensitivity and specificity of a score including all inotropes, vasopressors, and vasodilators listed in Appendix 1. This formula was inferior to the IS and VIS and was not further analyzed.
We calculated the maximum and mean IS and VIS in the first and second 24-hour periods after admission to the CICU. To account for vasoactive support over time, and for cases where a patient returned to the CICU on high support only to have it quickly weaned, we studied the mean IS/VIS. Mean IS/VIS was calculated by summing the hourly doses during the 24-hour period and dividing by 24. We also used the IS and VIS at hour 2 and compared this with the other measures. Patients were classified into one of the five mutually exclusive groups defined in our previous study (6) based on their scores at the different time points (Table 1 ) and assigned to the highest group achieved in either frame. For patients who reached a clinical endpoint (see next section below) in the first 48 hours, we did not use any IS or VIS scores after the event to calculate their maximum and mean scores or to classify them into the group framework. We chose to do this because we were interested in using VIS as a metric to predict eventual clinical outcome, and scores collected after an event (e.g., cardiac arrest or initiation of mechanical circulatory support) do not contribute meaningful data for that purpose.
Clinical Endpoints and Outcome Variables
The primary outcome for analysis was the dichotomous composite morbidity and mortality variable, termed "poor outcome," used in our previous analysis (6) . This outcome was reached if any of the following occurred: mortality (in-hospital or 30-day outof-hospital), cardiac arrest, use of mechanical circulatory support, renal replacement therapy, or neurologic injury (stroke or seizure). Secondary outcomes included CICU length of stay, time to first extubation, and need for reoperation requiring CPB. Patients with length of stay or time to extubation more than or equal to 75th percentile for the cohort were categorized as "prolonged" for analyses testing the association between IS/VIS and these metrics.
Statistical Analysis
Demographic and clinical characteristics were compared between two composite outcome groups and between centers, using chisquare test for categorical variables and t test, Wilcoxon rank sum test, analysis of variance, or Kruskal-Wallis test, as appropriate, for continuous variables. To determine the best metric in relation to poor outcome, the area under the receiver operating characteristic (ROC) curves of each maximum and mean value for each score formula (IS, VIS, and derivations) were compared. Optimal cut points for "high VIS" designation were then chosen using sensitivity and specificity from the ROC curve of the selected best metric. Odds ratios (ORs) with 95% CI were estimated using logistic regression to evaluate the relative odds of each clinical outcome, including the composite poor outcome variable, in the high VIS group compared with the low VIS group. In addition to analyzing the association between VIS and the composite clinical outcome, we also assessed the relationship between VIS and each of the individual endpoints separately.
Variables found to be significantly associated with the composite poor outcome in the univariate analyses (p < 0.05) were included in the multivariable analysis: age at surgery, surgical complexity category, stage 1 single-ventricle repair, and weight-for-age z score. Model fit was evaluated by Hosmer-Lemeshow goodnessof-fit test and a C-statistic. Posterior predicted probabilities of the composite outcomes at each VIS group were calculated using the fitted model with other covariates fixed at their mean values. . We controlled for center by including it as a fixed effect in each model to account for unmeasured practice differences between hospitals including extubation and CICU discharge criteria.
All analyses were performed with SAS Version 9.3 (SAS institute, Cary, NC) with statistical significance set at p values of less than 0.05 using two-sided tests. Descriptive statistics are presented as mean ± sd or median (interquartile range) as appropriate for continuous variables and frequency (percentage) for categorical variables. Statistics by center are not shown to prevent identification of the individual hospitals. 
RESULTS
Patient Characteristics and Center Variation
Three hundred ninety-one consecutive infants meeting eligibility criteria were enrolled in the study cohort. Demographic and clinical characteristics of the study population are shown in aggregate and based on composite outcome status in Table 2 .
The cohort included 141 neonates (36%) and 132 (34%) in STAT categories 4 or 5. Patients meeting the composite clinically derived poor outcome were younger, had more frequent preoperative vasoactive support, and were more likely to be in STAT categories 4 or 5 (all p < 0.05).
The frequencies of patient characteristics and utilization of therapies at each center were tabulated, and the ranges across centers are presented in Table 3 . Table 3 demonstrates the wide variation between centers in the use of individual vasoactive agents.
Comparing VIS and IS for Predicting Poor Outcome
The performance characteristics of IS and VIS for predicting a poor outcome are shown in Table 4 . Although both scores performed similarly, maximum VIS in the first 24 hours was selected for additional study based on the ease of calculation of a maximum value compared with a mean, inclusion of commonly used vasoactive agents not included in the IS, and being calculable within the first 24 postoperative hours. Other derivations of VIS and IS were not tested further.
Defining a High VIS Cut Point
Sensitivity and specificity from the ROC curve for predicting a poor outcome at each maximum VIS group in the first 24 hours suggested either group 3 or group 4 would be an appropriate metric to define high VIS (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww. com/PCC/A101). Although the group 3 cut point yielded the highest combined sensitivity and specificity, we opted to use group 4 and above to define high VIS because we wanted to maximize the specificity of our group designation. In subsequent analyses, patients with a maximum VIS in the first 24 hours of more than or equal to 20 (groups 4 or 5) were categorized as high VIS.
Estimating the Strength of Association between High VIS and Clinical Outcomes
Results of a multivariable logistic regression are shown in Table 5 . High VIS was significantly associated with the poor composite outcome (OR, 6.5; 95% CI, 2.9-14.6), with adequate model calibration (Pearson chi-square statistic = 7.5; p = 0.48) and good discrimination (C-statistic = 0.82). The observed and posterior predicted probabilities of a poor outcome based on group assignment using a maximum 24-hour VIS are shown in Figure 1 . 
DISCUSSION
This analysis demonstrated an association between maximum VIS in the first 24 hours after CICU admission and postoperative morbidity and mortality in children younger than 1 year following surgery with CPB. The metric we derived performs as well or better as a predictor of clinical outcome when compared with the IS or other derivations of an IS. Maximum VIS in the first 24 hours has biologic plausibility as a measure of illness severity and predictor of outcome as previous literature demonstrates a nadir in cardiac output after bypass (1), higher risk of cardiac arrest (11) , and peaking serum markers of inflammation (12) and myocardial injury (13, 14) during this time period.
We further determined a cutoff point for high VIS that discriminated patients with significantly greater odds of a poor clinical outcome and greater resource utilization compared with those with low VIS. The relationship between VIS and clinical outcome was demonstrated in a population of patients spanning a wider age range than previously reported and the association remained in stratified analyses by age and surgical complexity. Most importantly, our analysis demonstrates that the association between VIS and clinical outcomes holds in a multicenter cohort controlling for center effects.
Although we could not analyze every possible score for pharmacologic cardiovascular support, we tested several that can be calculated easily and early in the postoperative course and found results similar to our previous single-center cohort study. Another investigative team suggested that the optimal measure of VIS is the value at 48 hours after admission (8) , reasoning that sustained cardiovascular support over time may be more predictive of clinical outcome than a single maximum value. We tried to account for this possibility by calculating a mean VIS over the first 48 hours but found that this metric performed no better than the maximum VIS in the first 24 hours. We favor metrics that can be calculated as early in the postoperative course as possible in efforts to develop population-and individual-level risk prediction methods for CICU patients, similar to Acute Physiology and Chronic Health Evaluation (15) . These are desirable candidate variables because risk prediction calculated early in a patient's course may give clinicians the opportunity to change their therapeutic strategy based on predicted outcome. However, current models used for population-based risk adjustment are not necessarily adequate to predict individual patient risk (16) , and no illness-severity or risk-adjustment method currently applied to critically ill pediatric cardiac patients has been evaluated for this purpose. Studies performed after our original VIS publication raised doubt about the strength of association between VIS and outcomes in the neonatal population. Butts et al (7) showed that VIS was at most only modestly correlated with clinical outcomes and resource utilization in a cohort of neonates from a single-center series. In the current study, we analyzed a larger group of neonates from multiple centers and demonstrated strong associations between maximum VIS in the first 24 hours and clinical outcomes, including ventilator and CICU b OR represents odds of a poor outcome in high vasoactive-inotropic score (VIS) group (with maximum VIS in groups 4 and 5) relative to low VIS group (with maximum VIS in groups 1, 2, and 3) after controlling for centers, patient age, single-ventricle repair, STAT risk category, and weight-for-age z score. c p value from multivariable logistic regression after controlling for centers, patient age, single-ventricle repair, STAT risk category, and weight-for-age z score. length of stay. The reasons for the discrepancy between the two studies are not immediately clear, other than the methodologic differences in the analytic approach. There will be even greater opportunities in the future to define the association between VIS and outcomes in this important age subgroup as registries continue to develop and amass greater numbers of unique patient populations.
One of the inherent values of multicenter research, demonstrated in this study, is the ability to observe and describe practice variation among peer institutions. All four centers participating in this investigation are well-established programs with busy cardiac surgical services where children undergoing cardiac surgery are cared for in dedicated CICUs. Despite the similarities, it is clear from the descriptive data that institutional preferences for certain combinations of vasoactive agents vary widely.
Practice variation is likely driven in part by the lack of evidence to guide therapy around even the most basic pediatric CICU practices, like prescribing vasoactive drugs in the perioperative period. This lack of evidence emphasizes the need for focused efforts to develop an evidence base for common practices through sequential analyses. In this study, we utilized an existing clinical registry to provide standard patient and outcome data and then added a specific set of data variables to answer a hypothesis-driven research question. This approach markedly improves efficiency for data collection by using information for research that was already being collected with high fidelity as part of routine ICU operations. Future efforts to link critical care databases with other clinical and administrative registries (17) hold promise to provide answers to many questions related to best practice, value, and comparative effectiveness in the CICU. The next crucial step is to bridge the gap from data collection to quality improvement. Quality improvement collaboratives have played a key role in understanding the drivers of variation between hospitals around adult cardiac surgical outcomes and intervening to raise quality (18) . If datasets like those employed in this study can be used effectively by quality improvement collaboratives focused on perioperative care for pediatric cardiac surgical patients, then similar advances may be within reach in the near future.
These data should not be used to infer a causal relationship between high vasoactive support and clinical outcomes. There is usually important confounding by indication occurring when observing the relationship between vasoactive medication use and morbidity and mortality; the sickest patients receive the highest doses of drugs and more frequently receive third-and fourth-line agents. Our study design is inadequate to determine whether certain agents or drug combinations actually cause the observed morbidity and mortality, although that possibility certainly exists. An important question for future research is whether initiation of particular therapies (e.g., extracorporeal membrane oxygenation cannulation and therapeutic hypothermia) at a lower VIS is beneficial to patients compared with treatment with greater pharmacologic support.
It is a reasonable question whether therapy metrics are the most appropriate markers of disease severity. Most cardiac intensivists would likely prefer objective measurements of cardiac output or oxygen delivery, rather than the amount of vasoactive pharmacologic support, to describe the degree of cardiovascular dysfunction after surgery with CPB. However, these physiologic measurements are either unobtainable or subject to measurement error in most cases. Furthermore, in most instances, the agents used to calculate the VIS are only prescribed when cardiovascular support is indicated; it is logical to infer that if a patient is receiving vasoactive infusions, the treating clinician felt that treatment was required and that higher doses were necessary to treat a greater degree of dysfunction. Thus, we believe the VIS is an appropriate surrogate for illness severity based on the data presented herein.
In addition to the limitations noted previously regarding the exhaustiveness of score derivation and testing, there are other limitations in interpreting these data. Although this is the first multicenter cohort to study the association between vasoactive support and outcomes, the institutions participating in this study may not be representative of the entire CICU community. Furthermore, the results cannot be generalized to non-CPB cases or to older children undergoing surgery. Although our model showed good calibration and discrimination, the observed and predicted probabilities for a poor outcome in group 2 were higher than those in group 3, which cannot be easily explained. Future analyses will determine whether this is a chance finding in this cohort or a real phenomenon. Although this represents the largest cohort of patients undergoing cardiac surgery in which granular data on vasoactive agent use were collected, the relatively small study group limits the precision of our effect size estimates, though we were still able to show significant associations between high VIS and mortality alone, along with the individual morbidities.
Finally, we chose to approach this analysis using a standard methodology described above, culminating in a multivariable logistic regression. Other complementary and alternative methods exist for mining datasets to assess associations between independent variables and outcomes including, but not limited to, random forest, support vector machine, and nearest-neighbor interpolation. Datasets are likely to become more extensive in the future than the one used for this analysis through linkages between registries and incorporation of continuously captured information from bedside monitors and devices. Analyses of these larger databases may rely on these newer techniques listed here.
CONCLUSIONS
This study confirms the association between VIS and clinical outcomes after pediatric cardiac surgery for the first time in a multi-institutional cohort. VIS remains an attractive candidate variable for inclusion in a multivariable risk-adjustment or risk-prediction model in the CICU. Further work with larger datasets is necessary to understand more precisely how VIS functions as a predictor of outcome, how it performs in other important patient subgroups, and whether it can be combined with other candidate variables to create a unique illness-severity index for this patient population that predicts important clinical outcomes. This may be enhanced with more sophisticated "big data" analytic techniques appropriate for data structures more complex than those used in this study.
This study also demonstrates how efficient multicenter collaborative research can be in the pediatric CICU domain. In addition to shortening the timeline to achieve adequate sample size for analysis, a collaborative research environment reveals variation in practice patterns that should stimulate discussion and future scientific efforts to define an evidence base for CICU practice. Our method included supplementing an existing registry with additional data variables to answer a specific research question. Similar use of registries in future observational research and in clinical trials holds promise for facilitating scientific efforts in pediatric cardiac surgery and critical care.
